Literature DB >> 19909779

Polyglutamine-expanded ataxin-7 causes cerebellar dysfunction by inducing transcriptional dysregulation.

An-Hsun Chou1, Chia-Yang Chen, Si-Ying Chen, Wei-June Chen, Ying-Ling Chen, Yi-Shin Weng, Hung-Li Wang.   

Abstract

In the present study, we prepared an animal model of adult-onset spinocerebellar ataxia type 7 (SCA7) by generating transgenic mice expressing polyglutamine-expanded ataxin-7-Q52. Mutant ataxin-7-Q52 was expressed in brain areas implicated in SCA7 neurodegeneration, including cerebellum and inferior olivary nucleus. Ataxin-7-Q52 transgenic mice exhibited symptoms of motor dysfunction with an onset age of 7 months, and neurological phenotypes deteriorated in the following months. Ten to eleven-month-old ataxin-7-Q52 mice displayed ataxic symptoms without prominent cerebellar neuronal death, suggesting that ataxin-7-Q52 causes cerebellar malfunction and ataxia. To investigate the involvement of transcriptional dysregulation in ataxin-7-Q52-induced cerebellar dysfunction, microarray analysis and real-time RT-PCR assays were performed to identify altered cerebellar mRNA expressions of 10-11-month-old ataxin-7-Q52 transgenic mice. Ataxin-7-Q52 mice exhibited downregulated mRNA expressions of proteins involved in glutamatergic transmission, signal transduction, myelin formation, deubiquitination, axon transport, neuronal differentiation or glial functions and heat shock proteins. The involvement of transcriptional abnormality in initiating SCA7 pathological process was indicated by the finding that 6-month-old ataxin-7-Q52 transgenic mice, which did not display noticeable ataxic symptoms, exhibited dysregulated mRNA expressions. Our study suggests that polyglutamine-expanded ataxin-7-induced transcriptional dysregulation causes cerebellar dysfunction and ataxia. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909779     DOI: 10.1016/j.neuint.2009.11.003

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  26 in total

1.  Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration.

Authors:  Stephanie A Furrer; Mathini S Mohanachandran; Sarah M Waldherr; Christopher Chang; Vincent A Damian; Bryce L Sopher; Gwenn A Garden; Albert R La Spada
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 2.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

3.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

Review 4.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

5.  Genetic variation in ataxia gene ATXN7 influences cerebellar grey matter volume in healthy adults.

Authors:  Charlotte D C C van der Heijden; Mark Rijpkema; Alejandro Arias-Vásquez; Marina Hakobjan; Hans Scheffer; Guillen Fernandez; Barbara Franke; Bart P van de Warrenburg
Journal:  Cerebellum       Date:  2013-06       Impact factor: 3.847

6.  Aggregation of Polyglutamine-expanded Ataxin 7 Protein Specifically Sequesters Ubiquitin-specific Protease 22 and Deteriorates Its Deubiquitinating Function in the Spt-Ada-Gcn5-Acetyltransferase (SAGA) Complex.

Authors:  Hui Yang; Shuai Liu; Wen-Tian He; Jian Zhao; Lei-Lei Jiang; Hong-Yu Hu
Journal:  J Biol Chem       Date:  2015-07-20       Impact factor: 5.157

7.  Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7.

Authors:  Verónica M Borgonio-Cuadra; Claudia Valdez-Vargas; Sandra Romero-Córdoba; Alfredo Hidalgo-Miranda; Yessica Tapia-Guerrero; César M Cerecedo-Zapata; Oscar Hernández-Hernández; Bulmaro Cisneros; Jonathan J Magaña
Journal:  Mol Neurobiol       Date:  2019-02-05       Impact factor: 5.590

Review 8.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 9.  Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease.

Authors:  David D Bushart; Geoffrey G Murphy; Vikram G Shakkottai
Journal:  Ann Transl Med       Date:  2016-01

10.  Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts.

Authors:  Janine Scholefield; Lauren Watson; Danielle Smith; Jacquie Greenberg; Matthew J A Wood
Journal:  Eur J Hum Genet       Date:  2014-03-26       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.